271 related articles for article (PubMed ID: 17364571)
21. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
Elira Dokekias A; Okandze Elenga JP; Ndinga J; Sanogo I; Sangare A
Tunis Med; 2005 Jan; 83(1):32-7. PubMed ID: 15881719
[TBL] [Abstract][Full Text] [Related]
22. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
Nzouakou R; Bachir D; Lavaud A; Habibi A; Lee K; Lionnet F; Hulin A; Jouault H; Préhu C; Roudot-Thoraval F; Girot R; Galactéros F
Acta Haematol; 2011; 125(3):145-52. PubMed ID: 21196716
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea for the treatment of sickle cell anemia.
Platt OS
N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
[No Abstract] [Full Text] [Related]
24. [Effect of hydroxyurea on hemoglobin S].
Torres AF; Eberle SE; Sciuccati G; Bonduel M
Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
[TBL] [Abstract][Full Text] [Related]
25. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
26. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
de Montalembert M; Brousse V; Elie C; Bernaudin F; Shi J; Landais P;
Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381
[TBL] [Abstract][Full Text] [Related]
27. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
Khayat AS; Antunes LM; Guimarães AC; Bahia MO; Lemos JA; Cabral IR; Lima PD; Amorim MI; Cardoso PC; Smith MA; Santos RA; Burbano RR
Clin Exp Med; 2006 Mar; 6(1):33-7. PubMed ID: 16550342
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
Ritho J; Liu H; Hartzema AG; Lottenberg R
Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
[No Abstract] [Full Text] [Related]
30. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
Powars DR
J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
[No Abstract] [Full Text] [Related]
31. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
[TBL] [Abstract][Full Text] [Related]
32. Detection and assessment of stroke in patients with sickle cell disease: neuropsychological functioning and magnetic resonance imaging.
Gold JI; Johnson CB; Treadwell MJ; Hans N; Vichinsky E
Pediatr Hematol Oncol; 2008 Jun; 25(5):409-21. PubMed ID: 18569843
[TBL] [Abstract][Full Text] [Related]
33. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
de Montalembert M
Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.
Brachet C; Azzi N; Demulder A; Devalck C; Gourdin A; Gulbis B; Klein A; Le PQ; Loop M; Sariban E; Ferster A
Bone Marrow Transplant; 2004 Apr; 33(8):799-803. PubMed ID: 14767501
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
36. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
O'branski EE; Ware RE; Prose NS; Kinney TR
J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
[TBL] [Abstract][Full Text] [Related]
37. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
38. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
Fitzhugh CD; Wigfall DR; Ware RE
Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
[TBL] [Abstract][Full Text] [Related]
39. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
Al-Nood HA; Al-Khawlani MM; Al-Akwa A
Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
DeBaun MR
Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]